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Abstract
There is evidence that the atypical protein kinases C (PKCV, PKCj) participate in signaling from the insulin receptor to
cause the translocation of glucose transporters from an intracellular location to the plasma membrane in adipocytes. In order
to search for downstream effectors of these PKCs, we identified the proteins that were immunoprecipitated by an antibody
against PKCV/j from lysates of 3T3-L1 adipocytes through peptide sequencing by mass spectrometry. The data show that
PKCV is the major atypical PKC in these cells. Moreover, an oligomeric complex consisting of K- and Q-adducin, which are
cytoskeletal proteins, coimmunoprecipitated with PKCV. Association of the adducins with PKCV was further indicated by
the finding that the adducins coimmunoprecipitated proportionally with PKCV in repeated rounds of immunoprecipitation.
Such an association is consistent with literature reports that the adducins contain a single major site for PKC
phosphorylation in their carboxy termini. Using antibody against the phospho form of this site for immunoblotting, we
found that insulin caused little or no increase in the phosphorylation of this site on the adducins in a whole cell lysate or on
the small portion of the adducins that coimmunoprecipitated with PKCV. PKCV and the adducins were located in both the
cytosol and subcellular membranous fractions. The binding of PKCV to adducin may function to localize PKCV in 3T3-L1
adipocytes. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Insulin stimulates glucose transport in fat and
muscle cells by stimulating the tra⁄cking of the glu-
cose transporter GLUT4 from its intracellular loca-
tion to the plasma membrane [1,2]. This tra⁄cking
consists of the movement of intracellular storage
vesicles containing GLUT4 to the plasma membrane,
the docking of these vesicles at the membrane, and
the subsequent fusion of the vesicles with the mem-
brane [1,2]. It is not known which step or steps in the
tra⁄cking are stimulated by insulin. Moreover, the
complete signaling pathway or pathways from the
activated insulin receptor to the tra⁄cking process
are not known [2,3]. One partial insulin signaling
pathway that is known to be required for GLUT4
translocation is the pathway in which insulin acti-
vates phosphoinositide (PI) 3-kinase [2,3]. The acti-
vation of PI 3-kinase results in the elevation of PI
3,4,5-trisphosphate, which in turn leads to the acti-
vation of protein kinase B and of the atypical protein
kinases C (PKCV and PKCj) [4^7]. Some studies
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have presented evidence that activation of protein
kinase B participates in signaling GLUT4 transloca-
tion [8^12], and others have presented evidence that
activation of PKCV/j participates [13^17]. It may be
that both kinases do so. However, the substrate or
substrates of these kinases that are on the signal
transduction pathway for GLUT4 translocation
have not been identi¢ed.
Many kinases complex tightly with one or more of
their substrates [18]. In the present study we at-
tempted to ¢nd substrates of PKCV/j in 3T3-L1 adi-
pocytes by the approach of coimmunoprecipitation,
with the expectation that one of these substrates
might participate in signaling GLUT4 translocation.
3T3-L1 adipocytes were chosen, since these cells
show robust insulin-stimulated GLUT4 transloca-
tion, and insulin stimulates PKCV/j activity in these
cells by approx. 2.5-fold [13,15]. Moreover, experi-
ments in both 3T3-L1 adipocytes and rat adipocytes
with constitutively active PKCV/j, dominant negative
PKCV/j, and a PKCV interacting protein have pro-
vided evidence that PKCV/j participates in signaling
GLUT4 translocation in adipocytes [13^17]. Our re-
sults show that 3T3-L1 adipocytes express primarily
PKCV and indicate that a substantial portion of the
PKCV is complexed with the cytoskeletal protein ad-
ducin.
2. Materials and methods
2.1. Antibodies
An antibody against the carboxy terminal 20 ami-
no acid residues of mouse PKCj was purchased from
Santa Cruz Biotechnology (cat. No. sc216); this anti-
body also reacts with mouse PKCV, which di¡ers by
two amino acids in this sequence. Rabbit antiserum
against the carboxy terminal 204 amino acids of rat
Q-adducin [19] was a generous gift from Dr. Susan
Jaken at Lilly Research Laboratories. A mouse
monoclonal antibody against a phosphopeptide en-
compassing the PKC phosphorylation site of the ad-
ducins was raised against the sequence FRTPphos-
phoSFLKK, which is present in both K- and Q-
adducin. It reacts only with K-, L-, and Q-adducin
molecules that are phosphorylated on this site (V.
Bennett, unpublished results). The details of the
preparation and characterization of this antibody
will be reported elsewhere.
2.2. Cell culture and immunoprecipitations
3T3-L1 ¢broblasts were cultured and di¡erentiated
into adipocytes as described previously [20]. Just be-
fore use cells were incubated in serum-free medium
for 2 h. They were then left in the untreated state or
treated with insulin for the time period and at the
concentration given in the ¢gure legends. The cells
were then washed once with phosphate-bu¡ered sa-
line and lysed at 20‡C with 1 ml per 10 cm plate of a
lysis bu¡er consisting of 3% octaethylene glycol do-
decyl ether (C12E9 or Thesit, from Roche Molecular
Biochemicals) in 20 mM HEPES, 120 mM KCl,
5 mM MgCl2, pH 7.4 with phosphatase (10 mM
L-glycerol phosphate, 100 nM okadaic acid) and pro-
tease inhibitors (1 mM phenylmethanesulfonyl chlo-
ride, 10 WM EP475, 10 WM leupeptin, 1 WM pepsta-
tin). The lysate was centrifuged at 20 000Ug for
10 min at 4‡C to pellet the nuclei. The infranatant
was removed from the triglyceride and the pellet and
passed through a 0.22 Wm ¢lter (Gelman, cat. No.
4192) to remove traces of fat droplets. The lysate
cleared in this way was incubated for 2 h with anti-
body (10 Wg anti-PKCV, 10 Wg control rabbit immu-
noglobulin, or 5 Wl antiserum against Q-adducin per
ml lysate), and then the immunoadsorbates were col-
lected on protein A-Sepharose (Amersham Pharma-
cia Biotech) for 1.5 h. The beads were washed four
times with lysis bu¡er, and the adsorbed proteins
were released with SDS sample bu¡er containing
20 mM dithiothreitol and 8 M urea.
2.3. SDS^PAGE and protein sequencing
For analysis by protein staining, the immunopre-
cipitates were separated by SDS^PAGE on a 5^15%
gradient gel, and the proteins were then transferred
electrophoretically to nitrocellulose and stained with
colloidal gold (Bio-Rad). For amino acid sequencing,
PKCV was immunoprecipitated from 6 ml of lysate,
and the proteins in the immunoprecipitate were sep-
arated by SDS^PAGE on a 5^15% gradient gel. The
gel was stained with colloidal Coomassie blue
(Novex), and the protein bands to be sequenced
were cut from the gel.
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The protein bands were subjected to in-gel reduc-
tion, carboxyamidomethylation, and tryptic digestion
(Promega). Multiple peptide sequences were deter-
mined in a single run by microcapillary reverse-phase
chromatography directly coupled to a Finnigan LCQ
quadrupole ion trap mass spectrometer equipped
with a custom nanoelectrospray source. The column
was packed in-house with 5 cm of C18 support into a
New Objective one-piece 75 Wm internal diameter
column terminating in a 8.5 Wm tip. Flow rate was
190 nl per min. The ion trap was programmed to
acquire successive sets of three scan modes consisting
of: full scan mass spectrum (MS) over alternating
ranges of 395^800 m/z or 800^1300 m/z, followed
by two data dependent scans on the most abundant
ion in those full scale scans. These data dependent
scans allowed the automatic acquisition of a high
resolution (zoom) scan to determine charge state
and exact mass, and MS/MS spectra for peptide se-
quence information. MS/MS spectra were acquired
with a relative collision energy of 30% and an iso-
lation width of 2.5 Da, and recurring ions dynami-
cally excluded. Interpretation of the resulting MS/
MS spectra of the peptides was facilitated by pro-
grams developed at the Harvard Microchemistry Fa-
cility and by database correlation with the algorithm
Sequest [21,22].
2.4. Immunoblotting
Immunoblotting was carried out with samples of
the lysates, depleted lysates, and immunoprecipitates
described above. In addition, for the experiment de-
scribed in Fig. 3, 10 cm plates of 3T3-L1 adipocytes
were washed with phosphate-bu¡ered saline and
solubilized directly in 3 ml of SDS sample bu¡er
with 20 mM dithiothreitol. Proteins were separated
by SDS^PAGE and transferred electrophoretically to
Immobilon P (Millipore). The membranes were
blocked with 5% non-fat dry milk in 150 mM
NaCl, 20 mM Tris^Cl, pH 7.4 (TBS) and treated
with antibody in 1% milk in TBS at room temper-
ature for 2 h. The concentrations of the antibodies
were 1 Wg per ml for the antibody against PKCV, 0.2
Wg per ml for the antibody against phosphoadducin,
and 1/1000 dilution for serum against Q-adducin. De-
tection was with horseradish peroxidase-conjugated
secondary antibodies or protein A (Bio-Rad) and
the enhanced chemiluminescence reagent (Pierce).
2.5. Subcellular fractionation
3T3-L1 adipocytes were fractionated into cytosol,
mitochondria/nuclei, plasma membrane, and high
and low density microsomes, as described in [23].
3. Results
3.1. Proteins coimmunoprecipitating with PKCV
In an e¡ort to identify proteins associated with
PKCV/j in 3T3-L1 adipocytes, we immunoprecipi-
tated PKCV/j from lysates of basal and insulin-
treated 3T3-L1 adipocytes with an antibody against
the carboxy terminal peptide of both PKCV and
PKCj (see Section 2) and then analyzed the immu-
noprecipitates for coprecipitating proteins by SDS^
PAGE. As a control, immunoprecipitation was per-
formed with irrelevant immunoglobulin. Fig. 1
presents the results of such an experiment. Four pro-
tein bands, at approx. 72, 90, 116, and 160 kDa, were
Table 1
Proteins coimmunoprecipitating with PKCV
Banda Protein Database GI No. Size (aa) Peptides sequenced Sequence coverage (%)
1 PKCV 3452686 586 14 37
2 Q-adducin 1041240 671 13 23
3 K-adducin 1083589 735 12 22
p137 2498734 656 13 24
4 p160 3327162 1234 11b 15
aSee Fig. 1.
bThe protein in the table is human p160. Four of the peptides were present in it, and the remaining seven were present in translations
of mouse expressed sequence tags. The aa sequences of these expressed sequence tags showed that they were portions of the mouse
homologue of human p160.
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speci¢c to the PKCV/j immunoprecipitate (Fig. 1).
Insulin treatment did not result in a signi¢cant
change in the pattern of coimmunoprecipitating pro-
teins (compare lanes 1 and 2).
The PKCV/j immunoprecipitation was performed
on a large scale. The four protein bands were iso-
lated from a Coomassie blue-stained gel, and their
identities determined by peptide sequencing by mass
spectrometry, as described in Section 2. Table 1 sum-
marizes the results. The protein at 72 kDa was
PKCV. Although the antibody used for immunopre-
cipitation reacts with both PKCV and PKCj, of the
14 peptides sequenced from the 72 kDa band, 13
were unique to PKCV, one was common to PKCV
and PKCj, and none was unique to PKCj. Since
PKCV and PKCj migrate at the same position
upon SDS^PAGE [15], this ¢nding indicates that
PKCV is much more abundant than PKCj in 3T3-
L1 adipocytes. Kotani et al. have reached a similar
conclusion from analysis of 3T3-L1 adipocytes for
the two kinases by Northern and immunoblotting
[15].
The protein band at 90 kDa was identi¢ed as Q-
adducin, and the band at 116 kDa consisted of a
mixture of K-adducin and another protein, previ-
ously designated p137. There are three members of
the adducin family, designated K, L, and Q ; they are
closely related in amino acid sequences [24]. The ad-
ducins exist as heterodimers and heterotetramers
consisting of either the K/L or K/Q forms [24]. Thus,
the ¢nding of both K- and Q-adducin in the PKCV
immunoprecipitate is consistent with this informa-
tion on the oligomeric structures of the adducins.
The Coomassie blue staining intensities of the
PKCV, Q-adducin, and K-adducin bands in the prep-
arative gel used for sequencing were about the same
(data not shown). Similarly, the colloidal gold stain-
ing intensities of these three bands in the analytical
gel shown in Fig. 1 (lane 1) were about the same.
These observations suggest that a substantial portion
of the immunoprecipitated PKCV was complexed
with K/Q-adducin. However, the presence of p137 in
the K-adducin band and of a weakly stained back-
ground band arising from the antibody against
PKCV in the Q-adducin band (see lanes 1 and 5 of
Fig. 1) precludes precise determination of the relative
amounts of the three proteins in the PKCV immuno-
precipitate.
The p137 protein is the mouse homologue of hu-
man p137, a protein of unknown function that was
cloned from a human colon cDNA library [25]. This
protein has been shown to be an extracellular protein
that is linked to the plasma membrane by a glyco-
sylphosphatidylinositol linkage in human epithelial
cells [25]. Because of this location, it seems unlikely
that p137 would be associated with PKCV in intact
3T3-L1 adipocytes. For this reason we have not in-
vestigated p137 further.
The protein band at 160 kDa, which we have des-
ignated p160, was identi¢ed as the mouse homologue
of a human protein of unknown function whose
cDNA has been cloned as part of a large-scale
cDNA sequencing project [26]. This protein has a
predicted binding domain for the compound FK506
near its amino terminus [27]. We raised an antiserum
against the peptide LQGNSRRLSLTPDPEK from
Fig. 1. Proteins coimmunoprecipitating with PKCV. Immuno-
precipitates of PKCV from lysates of 3T3-L1 adipocytes in the
basal state (lane 2) and after treatment with 166 nM insulin for
10 min (lane 1) were separated by SDS^PAGE on a 5^15% gra-
dient gel. The proteins were then transferred to nitrocellulose
and stained with colloidal gold. For controls, lysates of basal
and insulin-treated adipocytes were immunoprecipitated with ir-
relevant rabbit immunoglobulin (IgG) in the same way (lanes 3
and 4). As an additional control, the antibody against PKCV
was added to the lysis bu¡er and collected in the same way on
protein A-Sepharose (lane 5). Each lane contained the immuno-
precipitate derived from two 10 cm plates of 3T3-L1 adipocytes
with 20 Wg of antibody. Known amounts of molecular weight
marker proteins (Bio-Rad) were run in the right hand lanes. A
repetition of this experiment gave similar results.
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mouse p160 and a⁄nity puri¢ed the antibody. The
a⁄nity-puri¢ed antibody both immunoblotted and
immunoprecipitated p160 from a 3T3-L1 adipocyte
lysate. However, when an immunoprecipitate of p160
from a lysate of the adipocytes was immunoblotted
for PKCV, no PKCV was detected (data not shown).
In a further e¡ort to determine whether PKCV and
p160 were associated, we performed three rounds of
immunoprecipitation of PKCV on a lysate of 3T3-L1
adipocytes and examined both the immunoprecipi-
tates and depleted lysates from each round for both
PKCV and p160 by immunoblotting. As expected,
the amount of PKCV in both the immunoprecipitate
and the depleted lysate from each round was less
than that from the previous round. However, only
a very small fraction of the p160, approx. 4%, was
coimmunoprecipitated in each round, and the
amount of p160 in the PKCV immunoprecipitate
and the depleted lysate did not detectably decrease
after each round of immunoprecipitation (data not
shown). These results, especially the ¢nding of a con-
stant amount of coimmunoprecipitated p160 with
each round despite decreasing amounts of immuno-
precipitated PKCV, suggest that the antibody against
PKCV bound directly to p160. Thus, cross-reaction
of p160 with the antibody against PKCV, rather than
association of p160 with PKCV, is probably the ex-
planation for the coimmunoprecipitation of p160. In
this regard, by computer analysis we could not ¢nd a
sequence in p160 with detectable similarity to the
peptide used to generate the antibody against PKCV.
Because of the relatively large amounts of the anti-
body heavy and light chains in the SDS samples in
Fig. 1, any protein of 60 kDa or less that coimmu-
noprecipitated with PKCV might have been obscured
by the strong staining of the antibody chains. In
order to examine the low molecular weight region
for coimmunoprecipitating proteins, the experiment
described in Fig. 1 was performed, except that the
immunoprecipitate was solubilized at 20‡C in SDS
sample bu¡er with 8 M urea and without reductant.
The unreduced antibody ran as a broad, heavily
stained band in the region between 90 and 200
kDa, and consequently it did not interfere with de-
tection of lower molecular weight proteins. The only
protein of low molecular weight detected in the
PKCV immunoprecipitate was one of approx. 55
kDa, and it was present in one experiment but not
in a repetition. This protein was sequenced and
found to be the lipoamide acyl transferase compo-
nent precursor of the branched chain K-ketoacid de-
hydrogenase complex (GI No. 1709438, size 482 ami-
no acids (aa)). Since this enzyme is mitochondrial
and since PKCV is not present in the mitochondria
(see Fig. 5), the two proteins are unlikely to be asso-
ciated in the intact cell.
3.2. Association of the adducin with PKCV
In order to investigate the potential interaction of
adducin with PKCV more fully, we immunoprecipi-
tated PKCV and adducin from lysates of basal and
insulin-treated 3T3-L1 adipocytes, and then immu-
noblotted the lysates, depleted lysates, and immuno-
Fig. 2. Coimmunoprecipitation of adducin with PKCV. (A) Ly-
sates of 3T3-L1 adipocytes in the basal state or after treatment
with 166 nM insulin for 10 min were immunoprecipitated with
antibody against PKCV or Q-adducin as described in Section 2.
Aliquots of the lysates (Lys), depleted lysates (dLys), and im-
munoprecipitates (IP) were immunoblotted for PKCV and Q-ad-
ducin. The 1U load is an amount derived from 1.5% of a 10
cm plate of adipocytes. (B) A lysate of adipocytes in the basal
state was subjected to three rounds of immunoprecipitation
with antibody against PKCV or irrelevant rabbit immunoglobu-
lin (IgG) as the control. The initial lysate and the depleted ly-
sates and immunoprecipitates from each round were immuno-
blotted for PKCV and Q-adducin. The 1U load was derived
from 1.5% of a 10 cm plate. Repetitions of these experiments
gave similar results.
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precipitates for PKCV and adducin (Fig. 2A). The
antibody against PKCV immunoprecipitated approx.
50% of the PKCV (Fig. 2A, compare lanes 1, 2 to
lanes 3, 4). As expected, the PKCV immunoprecipi-
tate contained adducin (Fig. 2A, lanes 5, 6). How-
ever, the amount of adducin that coimmunoprecipi-
tated with PKCV was only approx. 10% of the total
(compare lanes 5, 6 to lanes 1, 2). Although in Fig.
2A it appears that insulin treatment led to a slight
increase in the amount of adducin in the PKCV im-
munoprecipitate (compare lanes 5 and 6), in two
other experiments there was no di¡erence in the
amount of coimmunoprecipitating adducin in sam-
ples from basal and insulin-treated cells (for example,
see Fig. 4B). The antibody against adducin precipi-
tated approx. 50% of the adducin (compare lanes 7, 8
with 1, 2). However, no PKCV was detected in the
adducin immunoprecipitate (lanes 9, 10).
One possible explanation for the absence of PKCV
in the adducin immunoprecipitate is that the binding
sites on adducin for PKCV and the antibody against
adducin overlap, such that both cannot bind simul-
taneously. In fact, the antibody against Q-adducin
used here is against its carboxy terminal 204 amino
acids, and as described below, the PKC phosphory-
lation site in Q-adducin is located near its carboxy
terminus. An alternative explanation is that the anti-
body against PKCV cross-reacts directly with addu-
cin, even though by computer analysis neither K- nor
Q-adducin contains a peptide sequence with any sim-
ilarity to that of the PKCV peptide used to generate
the antibody against PKCV. In order to distinguish
between these possibilities, we performed three
rounds of immunoprecipitation of PKCV and ana-
lyzed the depleted lysates and immunoprecipitates
from each round for PKCV and adducin by immu-
noblotting (Fig. 2B). As expected, the amount of
PKCV in the depleted lysate and in the immunopre-
cipitate decreased with each round of immunopreci-
pitation (Fig. 2B, lanes 1^6 and lanes 7^9). More-
over, the amount of adducin that coimmuno-
precipitated with the PKCV also decreased with
each round in proportion with PKCV (lanes 7^9).
On the other hand, the amount of adducin in the
depleted lysate decreased only slightly, since only a
small portion of the adducin was immunoprecipi-
tated (lanes 1^6 and lanes 7^9). These results indicate
that adducin was immunoprecipitated because it was
associated with PKCV, rather than bound directly to
the antibody against PKCV. If the latter were the
case, it would be expected that approximately the
same amount of adducin would have been immuno-
precipitated in each round, since depleted lysate con-
tinued to contain most of the adducin. The conclu-
sion that adducin associates directly with PKCV is
consistent with an earlier study in which another
PKC isoform, PKCK, was shown to bind to a frag-
ment consisting of the carboxy terminal 204 aa of Q-
adducin in a blot overlay assay [28]. However, coim-
munoprecipitation of adducin with any PKC isoform
has not been found previously.
3.3. Phosphorylation of adducin
The three adducins are known substrates for PKC.
The site of PKC phosphorylation is a serine residue
in the carboxy terminus, which is nearly identical in
the three adducins [24]. The carboxy terminus is
highly positively charged; in K-adducin its sequence
is KKKKFRTPS*FLKKSKKKSDS. The serine
undergoing phosphorylation, which is marked by *,
is referred to as the RTPS site. As noted in Section 1,
insulin is reported to activate PKCV in 3T3-L1 adi-
pocytes. Maximal activation occurs at 5 min after
insulin treatment and is approx. 2.5-fold [15]. Con-
sequently, since adducin associates with PKCV, it
seemed likely that it might show increased phosphor-
ylation on the RTPS site in response to insulin. In
order to test this possibility, SDS lysates were pre-
pared from basal and insulin-treated 3T3-L1 adipo-
cytes and immunoblotted with an antibody speci¢c
for the phosphorylated RTPS site. Fig. 3 presents the
Fig. 3. Phosphorylation of adducin in basal and insulin-treated
3T3-L1 adipocytes. Matched 10 cm plates of 3T3-L1 adipocytes
were left in the basal state or treated for 5 min with 170 nM
insulin (experiments 1, 2) or 300 nM insulin (experiments 3, 4).
The plates were lysed in SDS sample bu¡er, and samples were
immunoblotted for phosphorylation at the RTPS site with the
phosphospeci¢c antibody. The 1U load is equivalent to 0.4%
(experiments 1, 2) or 0.1% (experiments 3, 4) of a 10 cm plate.
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results from four separate experiments in which the
cells were treated with insulin for 5 min. K-Adducin
was more highly phosphorylated than Q-adducin. In
experiments 1 and 2 insulin caused no increase in
phosphorylation, whereas in experiments 3 and 4 in-
sulin treatment appeared to cause a slight increase in
phosphorylation. In another experiment the phos-
phorylation of adducin after insulin treatment for
2, 5, 10, 30, and 60 min was examined, and the in-
sulin e¡ect at the other times was no greater than
that at 5 min (data not shown). From these data
we conclude that insulin caused little or no increase
in adducin phosphorylation on the RTPS site. As a
control for the e¡ectiveness of the insulin treatment,
it was shown by immunoblotting for phosphotyro-
sine that the insulin treatment elicited the phosphor-
ylation of the insulin receptor and insulin receptor
substrate 1 (data not shown). Although insulin
caused no signi¢cant increase in phosphorylation of
the adducin on the RTPS site, adducin was suscep-
tible to further phosphorylation on this site. Treat-
ment of the cells with phorbol myristate acetate at
1 WM for 15 min caused an approx. 3-fold increase in
phosphorylation of the RTPS site on both adducins
(data not shown). Phorbol myristate acetate activates
the conventional and novel PKCs [29], and it may
also activate PKCV, since phorbol myristate acetate
elevates PI 3,4,5-trisphosphate in 3T3-L1 adipocytes
[53].
It seemed possible that the small portion of the
adducin that was associated with PKCV might exhib-
it insulin-stimulated phosphorylation. Consequently,
we immunoprecipitated PKCV from basal and insu-
lin-treated adipocytes and then immunoblotted the
associated adducin for phosphorylation on the
RTPS site (Fig. 4). In fact, insulin caused no detect-
able increase in phosphorylation of the associated
adducin. The ratio of phosphorylated Q-adducin to
K-adducin was higher in the coimmunoprecipitating
adducin than in the total pool of adducin (compare
Figs. 3 and 4). Equal amounts of Q-adducin were
present in the PKCV immunoprecipitates from basal
and insulin-treated cells (Fig. 4, lower blot).
3.4. Subcellular distributions of PKCV and adducin
In order to determine the extent to which PKCV
and adducin are colocalized, we examined the sub-
cellular distributions of the two proteins (Fig. 5).
PKCV was approximately equally concentrated in
the cytosol, plasma membranes, and low density mi-
crosomes. By contrast adducin was most concen-
trated in the low density microsomes, and was also
abundant in the cytosol, plasma membranes, and
high density microsomes.
The low density microsomes consist of a mixture
of vesicles, largely derived from the endosomes, and
cytoskeletal elements; the high density microsomes
consist largely of endoplasmic reticulum and Golgi
[30,31]. Since the lanes in Fig. 5 were loaded with
equal amounts of protein, the relative intensities de-
pict the relative concentrations in the various frac-
Fig. 5. Subcellular distribution of PKCV and adducin in 3T3-
L1 adipocytes. 3T3-L1 adipocytes in the basal state and after
treatment with 1 WM insulin for 15 min were subjected to sub-
cellular fractionation. The fractions were immunoblotted for
PKCV and for Q-adducin. The fractions are: cytosol (Cyt), mi-
tochondria/nuclei (M/N), plasma membranes (PM), high density
microsomes (HDM), low density microsomes (LDM). The 1U
load was 20 Wg protein. A repetition of this experiment gave
the same results.
Fig. 4. Phosphorylation of the adducin coimmunoprecipitating
with PKCV. PKCV was immunoprecipitated from lysates of
matched 10 cm plates of 3T3-L1 adipocytes in the basal state
and after 300 nM insulin treatment for 5 min, as described in
Section 2. (A) The immunoprecipitates were immunoblotted for
phosphorylation at the RTPS site with the phosphospeci¢c anti-
body. (B) The immunoprecipitates were immunoblotted for Q-
adducin. The 1U load was derived from 1.6% of a 10 cm plate.
Two other repetitions of this experiment gave the same result.
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tions. The relative amounts of protein recovered in
the cytosol, plasma membrane, and high and low
density microsomes were approx. 1.0, 0.03, 0.10,
and 0.12, respectively (data not shown). Conse-
quently, because the amount of the cytosol protein
is 8-fold or more than that in the other fractions,
most of both the PKCV and adducin was in the
cytosol. Insulin treatment caused no signi¢cant
change in the subcellular distribution of either pro-
tein. The subcellular distribution of PKCV and the
lack on an insulin e¡ect upon it are in agreement
with the results of previous studies, although in these
the PKC was probably mistakenly identi¢ed as the
closely related j isoform [13,32].
4. Discussion
The search for interacting proteins by means of
coimmunoprecipitation has the advantage that it
provides a display of the associated proteins and
their relative amounts in the cell type of interest.
Our present results indicate that the major protein
interacting with PKCV in 3T3-L1 adipocytes is K/Q-
adducin. A large number of proteins have been pre-
viously found to be associated with PKCV/j in a
variety of cell types, but this is the ¢rst report of
an interaction with adducin. The previously identi-
¢ed interacting proteins include: Ras [33], protein
kinase B [34], p70 S6 kinase [35], protein kinase
PDK1 [5^7], casein kinase 2 [36], IUB kinase [37],
14-3-3 L/a [38], ¢broblast growth factor receptor sub-
strate 2 [39], a protein induced during apoptosis
known as par-4 [40], V-interacting protein [41], a hu-
man homologue of the Caenorhabditis elegans polar-
ity determinant par-6 [42], a human homologue of
the C. elegans unc-76 protein involved in axonal out-
growth [43], the VHL tumor suppressor protein [44],
a rat homologue of the C. elegans polarity protein
par-3 [17], and a protein variously named ZIP, p62,
EBIAP, and A170 [45]. It is somewhat surprising
that none of these 16 other proteins was found to
coimmunoprecipitate with PKCV from the lysates of
3T3-L1 adipocytes. There are several possible ex-
planations. The interacting protein may not be ex-
pressed in 3T3-L1 adipocytes, or the protein may be
expressed, but only a small portion of PKCV asso-
ciates with it. Also, some of these proteins may in-
teract with PKCV through the carboxy terminus of
the latter. Since the antibody used here for immuno-
precipitation of PKCV is against this region, it would
not be able to precipitate the PKCV with such a
protein associated. For example, it has been shown
that the kinase PDK1 associates with PKCj by asso-
ciation with its carboxy terminus [7]. In this regard,
to our knowledge it has not been previously noted
that the carboxy terminal sequences of PKCV and
PKCj, which are EESV and EECV, respectively,
are similar to the consensus sequence of a PDZ bind-
ing motif, which is ESXV [46]. The mammalian ho-
mologues of the C. elegans par-3 and par-6 proteins
that interact with PKCV/j have PDZ domains
[17,42].
The adducin heterodimer is a cytoskeletal protein
that binds to the ends and sides of actin ¢laments,
and recruits the protein spectrin to these sites [24,47].
Phosphorylation of the adducins by PKC at the car-
boxy terminal RTPS site inhibits the actin binding
and spectrin recruiting activities [47]. Moreover,
phosphorylation at this site correlates with changes
in the subcellular distribution of adducin in vivo
[47,48]. Our ¢nding that PKCV was associated with
adducin initially suggested that insulin treatment
might result in substantially enhanced phosphoryla-
tion of adducin via activation of PKCV. However,
insulin treatment of the 3T3-L1 adipocytes resulted
in only a small increase in phosphorylation of the
total adducin at the RTPS site, and no increase
was detected for the small portion of adducin asso-
ciated with PKCV. The small increase in phosphory-
lation of the total adducin could thus be due to its
phosphorylation either by PKCV and/or by another
PKC isoform that was activated by insulin. There is
evidence that insulin slightly activates PKCK and
PKCL in 3T3-L1 adipocytes [13].
It remains possible that the activation of PKCV by
insulin has e¡ects on adducin phosphorylation and
function that were not detected by the approaches
used here. The study showing adducin phosphoryla-
tion by PKC at the RTPS site employed a prepara-
tion of puri¢ed rat brain PKC that probably con-
sisted of a mixture of the conventional PKC
isotypes [24]. It is possible that PKCV, which is an
atypical PKC, phosphorylates a di¡erent site on the
adducins. The preferred substrate sequence motifs
for conventional and atypical PKCs have been found
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to be similar, but not identical [49]. If this were the
case, increased phosphorylation of adducin would
not have been detected with the phosphospeci¢c anti-
body for the RTPS site. A second possibility is that
an increase in the rate of phosphorylation at the
RTPS site in response to insulin is matched by an
increase in the rate of dephosphorylation, such that
there is an increase in £ux through the site but no net
increase in phosphorylation. Finally, it may be that
the small increase in phosphorylation of total addu-
cin at the RTPS site in response to insulin re£ects a
much larger increase in phosphorylation at this site
in a small portion of the adducin at a speci¢c critical
location in the cell.
Insulin enhances actin assembly at the periphery of
3T3-L1 adipocytes and causes membrane ru¥ing
[50]. There is evidence that this e¡ect, like the
GLUT4 translocation, is downstream from PI 3-ki-
nase [51]. Moreover, an intact actin cytoskeleton is
required for insulin-stimulated GLUT4 translocation
in 3T3-L1 and rat adipocytes, since depolymerization
of actin ¢laments with cytochalasin D or latrunculin
inhibits this process [51,52]. The interaction of PKCV
with adducin may function to localize PKCV to the
cytoskeleton, and this interaction may participate in
some way in the signaling of membrane ru¥ing and
GLUT4 translocation.
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